Loading…
Employees: 26
Size Bambusa Therapeutics (BBTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $791M, the 2377th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.90 on 18 Nov 2026.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | $0 | $0 |
| EBITDA | n/a | -$44.0M | -$13.9M |
| Net income | n/a | -$41.1M | -$13.7M |
| Free cash flow | n/a | -$39.8M | -$4.63M |
| Capital expenditure | n/a | $0 | $0 |
| Total debt | n/a | $135M | $14.0M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |